Imaging and Biomarkers of Hypoxia in Solid Tumors

To establish PET imaging with the tracer FMISO as an accurate and reliable method for measuring the oxygen content of a tumor and to establish the measurement of secreted markers in blood as an accurate and reliable method for measuring the oxygen content of a tumor.

Stanford is now accepting new patients for this trial. Please contact Laura Gable at 650-736-0798 for more information.



  • drug : EF5
  • drug : Carbogen
  • procedure : PET Scan

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

3.1.1 Eligible Diseases Any solid tumor malignancies of any stage meeting all of the following criteria: 1. Tumor is accessible for minimally invasive biopsy (i.e., not requiring general anesthesia; e.g., FNA, core needle, punch, excision under local anesthesia) OR surgical resection is the planned initial treatment regardless of participation in this study; 2. Minimum tumor dimension is at least 1 cm (to ensure it is above the detection threshold of PET imaging). Examples include but are not limited to: locally advanced squamous cell carcinoma of the head and neck to be treated by either initial surgery or primary chemoradiotherapy; inoperable non-small cell lung cancer or pancreatic carcinoma to be treated with stereotactic radiotherapy, which may be biopsied again at the time of percutaneous needle delivery of implanted fiducial markers. In addition, a subset of patients will be eligible for the carbogen breathing portion of the study if their initial 18F-EF5 scan demonstrates increased tumor uptake (tumor:blood ratio > 1.5). 3.1.2 Allowable type and amount of prior therapy: Patients with newly diagnosed malignancies should not have initiated treatment for their disease before participating in this study. Patients with recurrent or second malignancies may have had prior therapy as appropriate for their disease, but should have completed all prior treatment at least 30 days before participation in this study and should not have initiated new treatment for the current problem. 3.1.4 Patients must be greater than or equal to eighteen years of age. 3.1.5 ECOG or Karnofsky Performance Status will not be employed, but patients will need to be sufficiently healthy to tolerate all study procedures. 3.1.6 Requirements for organ and marrow function are not applicable to this study, but function will need to be sufficient to undergo planned therapy. 3.1.7 Ability to understand and the willingness to sign a written informed consent document.

External Links

Explore related trials

Contact information

Primary Contact:

Laura Gable 650-736-0798

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: